AOPT Plus Collagen May Ease Rosacea
Randomized trial suggests better short-term outcomes and lower recurrence at 24 weeks.
-
By
-
Andrea Surnit
-
May 13, 2026
-
Clinical Scorecard: AOPT Plus Collagen May Ease Rosacea
At a Glance
| Category | Detail |
|---|
| Condition | Rosacea |
| Key Mechanisms | Combination of advanced optimal pulse technology (AOPT) and recombinant human type III collagen dressings. |
| Target Population | Patients aged 18 to 50 years with congestive erythema and papulopustular lesions. |
| Care Setting | Clinical trial setting at The First Affiliated Hospital of Soochow University. |
Key Highlights
- Combination therapy showed a statistically significant improvement in overall response rate (89.3% vs 77.3%).
- Greater reductions in erythema, lesion severity, and pain scores were observed with combination therapy.
- Quality of life improved more significantly in the combination group across multiple domains.
- Lower recurrence rates at 24 weeks in the combination group (2.7% vs 14.7%).
- Adverse events were uncommon and similar between both treatment groups.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of rosacea based on clinical presentation including erythema and papulopustular lesions.
Management
- Consider combination therapy of AOPT and collagen dressings for improved outcomes.
Monitoring & Follow-up
- Monitor skin barrier measures and quality of life indicators post-treatment.
Risks
- Potential for recurrence of symptoms; adverse events are generally low.
Patient & Prescribing Data
150 patients enrolled in a clinical trial.
Collagen dressings applied post-AOPT sessions showed enhanced skin barrier function and reduced inflammatory markers.
Clinical Best Practices
- Utilize multimodal approaches targeting both vascular dysfunction and skin barrier impairment.
- Conduct larger multicenter trials for validation of findings.
Related Resources & Content
